Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
0 hedge funds and large institutions have $0 invested in Lumos Pharma, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.
25.72% less ownership
Funds ownership: 25.72% → 0% (-26%)
100% less funds holding
Funds holding: 28 → 0 (-28)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $8.08M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 28
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Private Advisor Group
Morristown,
New Jersey
|
-$2.88M |
| 2 |
Goldman Sachs
New York
|
-$1.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$945K |
| 4 |
Renaissance Technologies
New York
|
-$827K |
| 5 |
Jefferies Financial Group
New York
|
-$467K |
LUMO Hedge Fund Activity: Q4 2024 in Review
0 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2024, worth a combined $0 — down 100% from $8.08M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LUMO and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Private Advisor Group, exiting entirely with an estimated $2.88M sold.
- 0 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2024, down from 28 in Q3 2024.
- Funds reported $0 of Lumos Pharma, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2024 and 28 closed out, a net change of -28 holders.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2024 was Private Advisor Group, an estimated $2.88M sold.
Based on aggregated 13F filings for Q4 2024.